Effect of Kuanxiong Aerosol on Coronary Heart Disease angina patients: A multicenter Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007204

Enrollment

Unknown

Registered

2015-09-20

Start date

2011-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris of Coronary Heart Disease

Interventions

Treatment group:conventional western medicine therapy andkuanxiong aerosol

Control group: conventional western medicine therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with angina pectoris medicine diagnostic criteria andstandards of syndromes of traditional Chinese medicine (Heart Blood stasis type or qi stagnation andblood stasis type or cold-coagulation andblood-stasis type); 2. Age from 30 to 75 years old; 3. Freely given informed consent; 4. Angina attack frequency was three times or more in 1 week before into the group.

Exclusion criteria

Exclusion criteria: 1. The pregnancy or breast-feeding women; 2. Patients with participating in other clinical subjects at the same time; 3. Patients with alcohol allergy, nitrates prohibited andcareful use; 4. Ptients with cognitive impairment, unable to cooperate; 5. Patients with serious damage to liver andkidney function andmental abnormity.

Design outcomes

Primary

Measure	Time frame
The relief time of angina pectoris;	—

Secondary

Measure	Time frame
Electrocardiogram;	—

Countries

China

Contacts

Public ContactLizhi Li

lilizhi0723@aliyun.com+86 18618403219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026